Drug firm Dr Reddy's Laboratories on Monday said it has launched a biosimilar of Roche's Avastin in India indicated for the treatment of various types of cancers.
The company's biosimilar, Versavo, is available in strengths of 100 mg and 400 mg single use vials, Dr Reddy's said in a statement.
Commenting on the launch, Dr Reddy's India and Emerging Markets CEO M V Ramana said: "We regard the good health of our patients as our responsibility and are committed to ensure that they always have access to the medicines they need".
The launch of Versavo is another step in that journey and helps in strengthening the company's oncology portfolio, he added.
"Versavo will help improve access to high quality therapy at an affordable cost, addressing the needs of patients with different cancers in India," Dr Reddy's Biologics Global Head Raymond De Vre said.
According to lpsos India Tandem Oncology Monitor 2018, Avastin and its biosimilars had India sales of around Rs 223 crore (moving annual total) MAT for the most recent twelve months ending in December 2018, Dr Reddy's said.
The company now has six biosimilar products commercialised in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology space, it added.
Shares of Dr Reddy's Laboratories were trading at Rs 2,518.10 per scrip on BSE, up 1.01 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app